US2022030875A1PendingUtilityA1

Composition comprising antimicrobial metal ions and a quaternary cationic surfactant

Assignee: CONVATEC TECHNOLOGIES INCPriority: Apr 6, 2011Filed: Oct 20, 2021Published: Feb 3, 2022
Est. expiryApr 6, 2031(~4.7 yrs left)· nominal 20-yr term from priority
Inventors:David Parsons
A61K 33/38A61K 33/34A61K 33/32A61K 33/30A61K 33/26A61K 33/245A61K 31/14A61K 9/06A61K 9/0014A61P 17/02A61K 31/198A01N 37/44A61K 33/24A01N 33/12A61P 31/04A01N 59/20A01N 59/16A61P 31/00
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to an antimicrobial composition suitable for use on skin and wounds comprising a source of an antimicrobial metal ion and a quaternary cationic surfactant.

Claims

exact text as granted — not AI-modified
1 . An antimicrobial composition for treating wound bacteria in a biofilm, the composition comprising ionic silver, EDTA at a level of from 0.01% to 10% by weight, and a quaternary cationic surfactant, wherein the quaternary cationic surfactant is present at a level of more than or equal to 0.025% by weight, wherein the composition has a pH from 4 to 8, wherein the ionic silver, the EDTA, and the quaternary cationic surfactant are present in the composition in amounts that provide synergistic antimicrobial activity against the wound bacteria, and wherein the composition is in the form of a thin soluble film, the thin soluble film being suitable for lamination to a wound dressing. 
     
     
         2 . A composition as claimed in  claim 1 , wherein the ionic silver is present at a level of from 0.00001% to 1.0% by weight of the composition. 
     
     
         3 . A composition as claimed  claim 1 , wherein the cationic surfactant is selected from a group of the salts where the cation is benzethonium, benzalkonium, dimethyldiakylonium, alkylpyridinium and alkyltrimethylammonium. 
     
     
         4 . A composition as claimed in  claim 1 , wherein the quaternary cationic surfactant is present at a level of from 0.05% to 4% by weight. 
     
     
         5 . A composition as claimed in  claim 1 , wherein the EDTA is present as a di-, tri- or tetra-basic salt of EDTA. 
     
     
         6 . A composition as claimed in  claim 1 , wherein the EDTA is present in the composition at a level of 0.1% to 4% by weight of the composition. 
     
     
         7 . A process for making an antimicrobial wound dressing comprising:
 (i) obtaining an absorbent wound dressing, and   (ii) treating the wound dressing with an antimicrobial composition in the form of a thin soluble film, the thin soluble film being laminated to the wound dressing and for treating wound bacteria in a biofilm, wherein the composition comprises ionic silver, EDTA at a level of from 0.01% to 10% by weight, and a quaternary cationic surfactant, wherein the quaternary cationic surfactant is present at a level of more than or equal to 0.025% by weight, wherein the composition has a pH from 4 to 8, and wherein the ionic silver, the EDTA, and the quaternary cationic surfactant are present in the composition in amounts that provide synergistic antimicrobial activity against the wound bacteria.   
     
     
         8 . A composition as claimed in  claim 1 , wherein the quaternary cationic surfactant is selected from benzethonium chloride and benzalkonium chloride. 
     
     
         9 . A composition as claimed in  claim 1  having a pH from 4.5 to 5.5. 
     
     
         10 . A composition as claimed in  claim 1 , wherein the quaternary cationic surfactant is present at a level of from 0.5% to 2% by weight. 
     
     
         11 . A composition as claimed in  claim 1 , wherein the EDTA is present in the composition at a level of 0.2% to 1% by weight. 
     
     
         12 . A composition as claimed in  claim 1 , having a pH of about 5.5 to protect peri-wound tissue by not altering its pH balance. 
     
     
         13 . A process as claimed in  claim 12 , wherein the composition has a pH from 4.5 to 5.5. 
     
     
         14 . A process as claimed in  claim 12 , wherein the composition has a pH of about 5.5 to protect peri-wound tissue by not altering its pH balance. 
     
     
         15 . A process as claimed in  claim 12 , wherein the EDTA is present in the composition at a level of 0.2% to 1% by weight.

Join the waitlist — get patent alerts

Track US2022030875A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.